Sarah B. Noonberg is Chief Medical Officer for Maze Therapeutics, Inc. Dr. Noonberg is also on the board of Protagonist Therapeutics, Inc. and Neoleukin Therapeutics, Inc.

In her past career Dr. Noonberg was Chief Medical Officer for Prothena Corp. Plc, Chief Medical Officer at Nohla Therapeutics, Inc., Group VP & Head-Global Clinical Development at BioMarin Pharmaceutical, Inc., Director-Clinical Development at Chiron Corp. and SVP-Early Development & VP-Clinical Development at Medivation LLC (California).

Dr. Noonberg received a doctorate from The University of California, San Francisco, a doctorate from the University of California, Berkeley and an undergraduate degree from Dartmouth College.